Northwest Biotherapeutics, Inc.
NWBO
$0.2074
-$0.0026-1.24%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 17.63% | -23.68% | -71.91% | 33.14% | 28.40% |
| Total Depreciation and Amortization | 6.75% | 22.57% | 25.62% | 10.21% | 31.10% |
| Total Amortization of Deferred Charges | -24.52% | -32.18% | 4.35% | -44.55% | 21.26% |
| Total Other Non-Cash Items | -24.01% | -130.88% | 203.97% | -58.71% | -48.43% |
| Change in Net Operating Assets | 2,616.43% | -32.71% | 6,172.22% | -247.18% | 161.67% |
| Cash from Operations | 40.85% | -40.59% | -10.38% | -91.64% | 13.64% |
| Capital Expenditure | 59.73% | 58.29% | 82.07% | 80.65% | -58.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 59.73% | 58.29% | 82.07% | 80.65% | -58.33% |
| Total Debt Issued | -58.31% | 770.32% | -29.00% | 314.93% | 131.00% |
| Total Debt Repaid | -40,000.00% | -132.71% | -- | -76.77% | 98.00% |
| Issuance of Common Stock | 22,212.50% | 133.46% | 428.63% | -89.37% | -92.56% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -94.81% | 81.78% | 51.95% | -55.81% | -53.06% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -50.00% | -100.00% | 0.00% | -- | -- |
| Cash from Financing | -32.14% | 98.40% | -3.95% | 26.99% | 5.14% |
| Foreign Exchange rate Adjustments | -265.42% | 97.32% | 216.33% | 63.95% | -59.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -98.76% | 108.45% | 145.48% | -61.42% | 1.72% |
